Review of national spontaneous reporting schemes: Strengths and weaknesses

Adverse Drug Reactions and Toxicological Reviews

Volumn 21, Issue 4, 2002, Pages 231-241

  Hughes, M Louise ^a   Whittlesea, Cate M C ^a   Luscombe, David K ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS USED IN EMERGENCY MEDICINE; BIOLOGICAL PRODUCT; CONTACT LENS SOLUTION; DRUG; HERBACEOUS AGENT; HOMEOPATHIC AGENT; ILLICIT DRUG; IMMUNOLOGIC AGENT; INSECTICIDE; RADIOPHARMACEUTICAL AGENT; VACCINE;

ARTICLE; AUSTRALIA; CANADA; COMPARATIVE STUDY; CONGENITAL MALFORMATION; CONTRACEPTIVE DEVICE; CONTROLLED STUDY; DENMARK; DENTIST; DEVICE; DRUG INDUCED DISEASE; DRUG INFORMATION; DRUG MONITORING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FRANCE; HEALTH CARE; HEALTH HAZARD; HEALTH PRACTITIONER; HEALTH SERVICE; HEALTH SURVEY; HUMAN; LEGAL ASPECT; PHARMACIST; PHYSICIAN; SIDE EFFECT; SOUTH AFRICA; SPAIN; UNITED STATES; VACCINATION REACTION; WORLD HEALTH ORGANIZATION;

EID: 0036912585     PISSN: 0964198X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03256199     Document Type: Article

References (34)

1. Griffin JP. Survey of the spontaneous adverse drug reaction reporting schemes in fifteen countries. Br J Clin Pharmacol 1986; 22: 83S-100S
2. Edwards IR. Spontaneous reporting: Of what? Clinical concerns about drugs. Br J Clin Pharmacol 1999; 48: 138-41
3. McGettigan P, Feely J. Adverse drug reaction reporting: Opinions and attitudes of medical practitioners in Ireland. Pharmacoepidemiol Drug Saf 1995; 4: 355-8
4. World Health Organization. WHO Programme [online]. Available from URL: http://www.who.pharmasoft.se/umc.html [Accessed 2000 Aug 31]
5. Van Boxtel CJ. Strategies for PMS of new drugs in the EC. Pharmacoepidemiol Drug Saf 1993; 2: S7-S10
6. World Health Organization. About UMC [online]. Available from URL: http://www.who.pharmasoft.se/umc.html [Accessed 2000 Aug 31]
7. Rawlins MD. Spontaneous reporting of adverse drug reactions. I: The data. Br J Clin Pharmacol 1988; 26: 1-5
8. Better ADR alerting needed in the UK. Scrip 1999; 2482: 7
9. Roeser HP, Rohan AP. Post-marketing surveillance of drugs. The spontaneous reporting scheme: Role of the Adverse Drug Reactions Advisory Committee. Med J Aust 1990; 153: 720-6
10. Bem JL, Wood SM, West L, et al. 25 years of the Committee on Safety of Medicines: An international perspective of the benefits. Drug Saf 1990; 5: 161-7
11. 'Yellow card' reporting now allowed for all community pharmacists. Pharm J 1999; 263: 776
12. Davis S, Coulson R. Community pharmacist reporting of suspected ADRs: (1) the first year of the yellow card demonstration scheme. Pharm J 1999; 263: 786-8
13. Royer RJ. Pharmacovigilance: The French system. Drug Saf 1990; 5 Suppl. 1: 137-40
14. Wood SM, Coulson R. Adverse drug reactions on-line information tracking (ADROIT). Pharm Med 1993; 7: 203-13
15. Mann RD. Prescription event monitoring: Recent progress and future horizons. Br J Clin Pharmacol 1998; 46: 195-201
16. Committee on Safety of Medicines, Medicines Control Agency. HIV adverse drug reactions reporting scheme. Curr Probl Pharmacovigil 1998 Mar; 24: 3
17. Committee on Safety of Medicines, Medicines Control Agency. A new reporting initiative for paediatric adverse drug reactions in the Trent region. Curr Probl Pharmacovigil 1999 Feb; 25: 4
18. Committee on Safety of Medicines. Welcome to the yellow card adverse drug reactions reporting scheme pages [online]. Available from URL: http://ftp.open.gov.uk/mca/csmhome.htm [Accessed 2000 Apr 13]
19. United Nations. Estimates of mid-year population 1986-1995. In: Demographic Yearbook 1995. New York: United Nations, 1997; 47: 152-9
20. Koch-Weser J, Sellers EM, Zacest R. The ambiguity of adverse drug reactions. Eur J Clin Pharmacol 1977; 11: 75-8
21. Wilholm BE, Olsson S, Moore N, et al. Spontaneous reporting schemes outside the United States. In: Strom BL, editor. Pharmacoepidemiology. 3rd rev. ed. Chichester: John Wiley and Sons Ltd, 2000: 175-92
22. Health Canada. Adverse drug reaction reporting: 1999. Can Adverse Drug React News 2000; 10: 1
23. Sills JM, Tanner LA, Milstein JB. Food and drug administration monitoring of adverse drug reactions. Am J Hosp Pharm 1986; 43: 2764-70
24. Edwards C, Smith JM, Bateman DN, et al. Adverse drug reaction monitoring in hospitals: A study of a pharmacy (green card) monitoring scheme in the Northern region [abstract]. Pharm J 1989; 243: R48
25. Hall M, McCormack P, Arthurs N, et al. The spontaneous reporting of adverse drug reactions by nurses. Br J Clin Pharmacol 1995; 40: 173-5
26. Egberts TCG, Smulders M, De Konig FHP, et al. Can adverse drug reactions be detected earlier?: A comparison of reports by patients and professionals. BMJ 1996; 313: 530-1
27. Mitchell AS, Henry DA, Hennrikus D, et al. Adverse drug reactions: Can consumers provide early warning? Pharmacoepidemiol Drug Saf 1994; 3: 257-64
28. Fisher S, Bryant SG. Postmarketing surveillance: Accuracy of patient drug attribution judgements. Clin Pharmacol Ther 1990; 48: 102-7
29. Fisher S, Bryant SG, Kent TA, et al. Patient drug attributions and postmarketing surveillance. Pharmacotherapy 1994; 14: 202-9
30. Kennedy DL, Goldman SA, Lillie RB. Spontaneous reporting in the United States. In: Strom BL, editor. Pharmacoepidemiology. 3rd rev. ed. Chichester: John Wiley and Sons Ltd, 2000: 151-74
31. Department of Health. The Expert Patient: A New Approach to Chronic Disease Management for the 21st Century. London: Department of Health, 2001
32. Inman WHW, Weber JCP. The United Kingdom. In: Inman WHW, editor. Monitoring for Drug Safety. 2nd ed. Lancaster: MTP, 1986: 37
33. Rogers AS, Israel E, Smith CR, et al. Physician knowledge, attitudes and behaviour related to reporting adverse drug events. Arch Intern Med 1988; 148: 1596-600
34. Randhawa HK, Smith JC, Irvin LE. Hospital doctors' attitudes to adverse drug reactions and their reporting. Pharm J 1987; 238: 739-95